Neurogene, Inc./$NGNE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Neurogene, Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Ticker
$NGNE
Sector
Primary listing
Employees
131
Headquarters
Website
Neurogene, Inc. Metrics
BasicAdvanced
$670m
-
-$4.56
2.08
-
Price and volume
Market cap
$670m
Beta
2.08
52-week high
$43.66
52-week low
$15.93
Average daily volume
279k
Financial strength
Current ratio
13.079
Quick ratio
12.903
Long term debt to equity
2.558
Total debt to equity
3.84
Interest coverage (TTM)
-36,879.33%
Profitability
EBITDA (TTM)
-107.454
Management effectiveness
Return on assets (TTM)
-23.91%
Return on equity (TTM)
-37.25%
Valuation
Price to book
2.21
Price to tangible book (TTM)
2.21
Price to free cash flow (TTM)
-8.745
Free cash flow yield (TTM)
-11.44%
Free cash flow per share (TTM)
-3.842
Growth
Earnings per share change (TTM)
4.72%
3-year earnings per share growth (CAGR)
-66.44%
Neurogene, Inc. News
AllArticlesVideos
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·4 weeks ago
Neurogene Inc. Announces Pricing of $125 Million Public Offering
Business Wire·1 month ago
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.